Ruffer LLP Purchases New Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Ruffer LLP acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 3rd quarter, Holdings Channel reports. The institutional investor acquired 55,385 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,647,000.

A number of other hedge funds have also recently bought and sold shares of SUPN. Rubric Capital Management LP acquired a new position in shares of Supernus Pharmaceuticals during the second quarter valued at $21,908,000. Sofinnova Investments Inc. raised its stake in shares of Supernus Pharmaceuticals by 53.5% during the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after buying an additional 278,575 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in Supernus Pharmaceuticals by 134.2% in the second quarter. Qube Research & Technologies Ltd now owns 229,710 shares of the specialty pharmaceutical company’s stock valued at $7,240,000 after buying an additional 131,632 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $3,869,000. Finally, Millennium Management LLC boosted its stake in Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after acquiring an additional 112,886 shares during the last quarter.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. TD Cowen boosted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Bank of America initiated coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price on the stock. Zacks Research lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, December 8th. Finally, Stifel Nicolaus upped their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $61.60.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the sale, the senior vice president owned 15,496 shares in the company, valued at $781,153.36. The trade was a 56.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $48.94 on Thursday. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $57.65. The company has a market cap of $2.81 billion, a P/E ratio of -143.94, a P/E/G ratio of 0.43 and a beta of 0.67. The stock’s 50-day simple moving average is $48.62 and its 200 day simple moving average is $45.98.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The company had revenue of $170.00 million during the quarter, compared to the consensus estimate of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.69 earnings per share. As a group, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.